Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin
Conclusion.Baseline heart rate and the frequency of hypomagnesemia episodes during treatment are prognostic of survival for patients with advanced ovarian cancer receiving carboplatin‐containing chemotherapy and tumor reductive surgery. Future research is needed for strategies to detect and prevent hypomagnesemia in this patient population.Implications for Practice.Despite standard laboratory tests and intravenous magnesium replacement prior to each cycle of chemotherapy, hypomagnesemia remains a common side effect of platinum‐based chemotherapy. This study revealed that frequent occurrence of hypomagnesemia during the course of treatment including carboplatin‐containing chemotherapy and tumor reductive surgery was strongly predictive of shorter survival in patients with advanced ovarian cancer. Strategies to effectively mitigate hypomagnesemia, such as more frequent detection, dietary recommendations, and timely replacement, should be considered in the overall cancer treatment plan for these patients.
Source: The Oncologist - Category: Cancer & Oncology Authors: Wenli Liu, Aiham Qdaisat, Pamela T. Soliman, Lois Ramondetta, Gabriel Lopez, Santhosshi Narayanan, Shouhao Zhou, Lorenzo Cohen, Eduardo Bruera, Sai-Ching J. Yeung Tags: Gynecologic Oncology, Head and Neck Cancers Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Diets | Head and Neck Cancer | Heart | Laboratory Medicine | Magnesium | Nutrition | OBGYN | Ovarian Cancer | Ovaries | Pathology | Serous Carcinoma | Study